Royal Bank Of Canada Cue Biopharma, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.24 - $2.18 $1,062 - $1,868	-857 Reduced 85.7%	143 $0
Q1 2024 Nov 05, 2024	BUY	$1.77 - $3.09 $1,516 - $2,648	857 Added 599.3%	1,000 $1,000
Q1 2024 May 15, 2024	SELL	$1.77 - $3.09 $20,284 - $35,411	-11,460 Reduced 91.97%	1,000 $1,000
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.1 $3,675 - $6,624	2,137 Added 20.7%	12,460 $32,000
Q3 2023 Nov 14, 2023	BUY	$2.23 - $4.69 $18,236 - $38,354	8,178 Added 381.26%	10,323 $23,000
Q2 2023 Aug 14, 2023	BUY	$3.11 - $4.91 $6,670 - $10,531	2,145 New	2,145 $7,000
Q3 2022 Nov 14, 2022	BUY	$2.23 - $3.37 $443 - $670	199 Added 995.0%	219 $0
Q2 2022 Aug 15, 2022	SELL	$2.49 - $5.92 $6,573 - $15,628	-2,640 Reduced 99.25%	20 $0
Q1 2022 May 16, 2022	SELL	$4.41 - $12.28 $17,811 - $49,598	-4,039 Reduced 60.29%	2,660 $13,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $41,789 - $68,686	3,848 Added 134.97%	6,699 $76,000
Q3 2021 Nov 15, 2021	BUY	$10.06 - $15.3 $8,168 - $12,423	812 Added 39.82%	2,851 $42,000
Q2 2021 Aug 16, 2021	BUY	$10.9 - $14.53 $22,225 - $29,626	2,039 New	2,039 $24,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.